

NCPE Assessment

Plain English Summary

January, 2025

Drug name: Brexucabtagene autoleucel
(pronounced brek-suh-KAB-tuh-jeen
AW-toh-LOO-sel) for the treatment
of adult patients 26 years of age and
above with relapsed or refractory B-
cell precursor acute lymphoblastic
leukaemia

Brand name: Tecartus®

HTA ID: 23045

What is the NCPE?

The National Centre for Pharmacoeconomics (NCPE) is a team of experts who look at the health benefits and costs of medicines. The HSE asks us to advise on whether or not a new medicine is good value for money. We give unbiased advice to help the HSE provide the most effective, safe and cost-effective (value for money) treatments for patients.

How do we make our recommendations?

Our main focus is on the health benefits and cost effectiveness of a medicine. We look at the wider costs and health benefits associated with a new medicine, for example:

- Does the new medicine work better than other treatments available in Ireland?
- Is the new medicine easier to give or easier to take compared with other treatments available in Ireland?
- Does the new medicine reduce the need for patients to be hospitalised?
- Does the new medicine improve the quality of a patient's life over other treatments available in Ireland?
- Will the new medicine save resources elsewhere within the health system?

We review the information from clinical trials along with the cost and value for money data presented by the pharmaceutical company. We ask doctors and other healthcare professionals for advice about any health benefits of the new medicine compared with current treatments. We also ask patient organisations to send us their views on how the new drug may improve patients' day-to-day experience of living with a disease.

What is brexucabtagene autoleucl used for?

Brexucabtagene autoleucl is a cancer medicine used to treat adults, 26 years of age and older, with acute lymphoblastic leukaemia (a cancer of B cells, a type of white blood cell) when the cancer has come back or did not respond to previous treatments. Treatment with brexucabtagene autoleucl uses the patient's own white blood cells. The patient's own white blood cells are extracted from the patient's blood and are genetically modified in the laboratory. The modified white blood cells are then given to the patient as a single infusion

(drip) into a vein. The infusion of modified white blood cells is only given to the patient whose white blood cells were used to make it.

What recommendation has the NCPE made to the HSE?

We have recommended that the HSE should consider not funding brexucabtagene autoleucel unless its cost effectiveness (value for money) can be improved. The HSE will consider our recommendation and make the final decision about reimbursement (funding). When making the funding decision, the HSE will also consider the additional [criteria](#) outlined in the Health (Pricing and Supply of Medical Goods) Act 2013.

Why did we make this recommendation?

After reviewing the data presented by the pharmaceutical company, we concluded that it is not clear that brexucabtagene autoleucel works as well or better than other ways to manage this condition. The price of the medicine is too high compared with other ways to manage this condition, and we believe that the medicine is very poor value for money. We recommend that the HSE consider not providing this medicine unless the HSE can agree a suitable price reduction with the pharmaceutical company.

The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

Next steps

When the HSE receives our recommendation, it will look at all the relevant data about brexucabtagene autoleucel. The HSE makes the final decision on reimbursement.

Where can I get more information?

You can get more information about brexucabtagene autoleucel from the following online options:

- The NCPE Technical Summary Document
- Tecartus European Public Assessment Report (EPAR) – [Summary for the public](#)

- Searching for brexucabtagene autoleucl on our website (www.ncpe.ie)
- Searching for brexucabtagene autoleucl on the European Medicines Agency (EMA) website (www.ema.europa.eu).

Please refer to the NCPE website for updated information on the reimbursement status of this medicine